PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
6.22%
Cash & equivalents growing 6.22% while AVXL's declined -72.20%. Peter Lynch would see this as a sign of superior liquidity management.
-100.00%
Both AVXL and the company show zero Short-Term Investments Growth.
6.22%
Below half of AVXL's -72.20%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Higher Other Current Assets Growth compared to AVXL's zero value, indicating worse performance.
13.80%
Below half of AVXL's -62.19%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
2.11%
Higher PP&E (Net) Growth compared to AVXL's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2.11%
Higher Total Non-Current Assets Growth compared to AVXL's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
13.78%
Below half of AVXL's -61.65%. Michael Burry sees a potential red flag for stagnation or capital shortage.
62.36%
Less than half of AVXL's -6.98%. David Dodd sees a more disciplined AP approach or lower volume.
-40.14%
Above 1.5x AVXL's -4.98%. Michael Burry sees a major discrepancy in short-term leverage. Check coverage and liquidity carefully.
No Data
No Data available this quarter, please select a different quarter.
133.46%
≥ 1.5x AVXL's 6.98%. David Dodd sees stronger subscription/prepayment demand.
184.58%
Less than half of AVXL's -5.24%. David Dodd sees fewer expansions in other current obligations.
173.41%
Less than half of AVXL's -6.74%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
173.41%
Less than half of AVXL's -36.25%. David Dodd sees far fewer liability expansions relative to competitor.
4.06%
Above 1.5x AVXL's 1.08%. Michael Burry suspects heavy new equity expansion or dilution.
-25.11%
Below half AVXL's 0.87%. Michael Burry suspects major net losses or high dividends vs. competitor.
-90.06%
Less than half of AVXL's 96.59%. David Dodd sees fewer intangible or market-driven swings than competitor.
-100.00%
Higher Other Stockholders' Equity Items Growth compared to AVXL's zero value, indicating worse performance.
-763.59%
Below half AVXL's 32.19%. Michael Burry sees potential underperformance in building shareholder capital.
13.78%
Below half AVXL's -61.65%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
-100.00%
Both AVXL and the company show zero Total Investments Growth.
-40.14%
Above 1.5x AVXL's -4.98%. Michael Burry sees a major jump. Investigate leverage rationale.
-7.59%
Less than half of AVXL's 177.82%. David Dodd sees better deleveraging or stronger cash buildup than competitor.